Zinc complexes developed as metallopharmaceutics for treating diabetes mellitus based on the bio-medicinal inorganic chemistry

Current Topics in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 210-218

  Yoshikawa, Yutaka ^a   Yasui, Hiroyuki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Anti diabetic zinc complexes; Bio coordination chemistry; Bioinorganic chemistry; Diabetes mellitus; Insulin signaling; Medicinal inorganic chemistry; Metallopharmaceutics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; HEMOGLOBIN A1C; MEGLITINIDE; SULFONYLUREA; ZINC COMPLEX;

ABDOMINAL CRAMP; ANEMIA; ANTIDIABETIC ACTIVITY; BLEEDING; DIABETES MELLITUS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG MEGADOSE; DRUG STRUCTURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOLOGICAL PARAMETERS; LD 50; LEUKOPENIA; NAUSEA; NONHUMAN; PROSTATE CANCER; REVIEW; SIDE EFFECT; TENESMUS; VOMITING;

ANIMALS; COORDINATION COMPLEXES; DIABETES MELLITUS; DRUG DESIGN; HUMANS; METALS, HEAVY; ORGANOMETALLIC COMPOUNDS; TRACE ELEMENTS; TRANSITION ELEMENTS; ZINC;

EID: 84856458633     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799078874     Document Type: Review

References (88)

1. Abrams, M. J.; Murrer, B. A. Metal compounds in therapy and diagnosis. Science, 1993, 261, 725-730.
2. Guo, Z.; Sadler, P. J. Metals in medicine. Angew. Chem. Int. Ed., 1999, 38, 1512-1531.
3. Thompson, K. H.; Orvig, C. Boon and bane of metal ions in medicine. Science, 2003, 300, 936-939.
4. Respondek, J.; Engel, J. Organometallics in medicine. Drugs Future, 1996, 21, 391-408.
5. Meggers, E.; Atilla-Gockcumen, G. E.; Bregman, H.; Maksimoska, J.; Mulcahy, S. P.; Pagano, N.; Williams, D. S. Exploring chemical space with organometallics: ruthenium complexes as protein kinase inhibitors. Synlett, 2007, 1177-1189.
6. Sakurai, H.; Kojima, Y.; Yoshikawa, Y.; Kawabe, K.; Yasui, H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coord. Chem. Rev., 2002, 226, 187-198.
7. Sakurai, H.; Yoshikawa, Y.; Yasui, H. Current state for the development of metallopharmaceutics and anti-diabetic metal complexes. Chem. Soc. Rev., 2008, 37, 2383-2392.
8. Underwood, E. J. Trace Elements in Human and Animal Nutrition, 4th ed., Academic Press, 1977, 545pp.
9. Vallee, B. L.; Falchuk, K. H. The biochemical basis of zinc physiology. Physiol. Rev., 1993, 73, 79-118.
10. Auld, D. S. Zinc coordination sphere in biochemical zinc sites. BioMetals, 2001, 14, 271-313.
11. Hanas, J. S.; Hazuda, D.; Bogenhagen, D. F.; Wu, F. Y.-H.; Wu, C.-W. Xenopus transcription factor A requires zinc for binding to the 5 S RNA gene. J. Biol. Chem., 1983, 258, 14120-14125.
12. Miller, J.; McLachlan A. D.; Klug, A. Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J., 1985, 4, 1609-1614.
13. Laity, J. H.; Lee, B. M.; Wright, P. E. Zinc finger proteins: new insights into structural and functional diversity. Curr. Opin. Struct. Biol., 2001, 11, 39-46.
14. Palmiter, R. D.; Findley, S. D. Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J., 1995, 14, 639-649.
15. Maret, W.; Vallee, B. L. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc. Natl. Acad. Sci. USA, 1998, 95, 3478-3482.
16. Frederickson, C. J.; Su, S. W.; Silva, D.; Thompson, R. B. Importance of zinc in the central nervous system: the zinc-containing neuron. J. Nutr., 2000, 130, 1471S-1483S.
17. Wang, K.; Zhou, B.; Kuo, Y. M.; Zemansky, J.; Gitschier, J. A. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am. J. Hum. Genet., 2002, 71, 66-73.
18. Kury, S.; Dreno, B.; Bezieau, S.; Giraudet, S.; Kharfi, M.; Kamoun, R.; et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat. Genet., 2002, 31, 239-240.
19. Hurley, L. S.; Shrader, R. E. Abnormal development of preimplantation rat eggs after three days of maternal dietary zinc deficiency. Nature, 1975, 254, 427-429.
20. Golub, M. S.; Keen, C. L.; Gershwin, M. E.; Hendrickx, A. G. Developmental zinc deficiency and behavior. J. Nutr., 1995, 125, 2263S-2271S.
21. Berg, J. M.; Shi, Y. The galvanization of biology: a growing appreciation for the roles of zinc. Science, 1996, 271, 1081-1085.
22. Wellinghausen, N.; Kirchner, H.; Rink, L. The immunobiology of zinc. Immunol. Today, 1997, 18, 519-521.
23. Grahn, B. H.; Paterson, P. G.; Gottschall-Pass, K. T.; Zhang, Z. Zinc and the eye. J. Am. Coll. Nutr., 2001, 20, 106-118.
24. Fraker, P. J.; King, L. E. Reprogramming of the immune system during zinc deficiency. Annu. Rev. Nutr., 2004, 24, 277-298.
25. Dvergsten, C. L.; Fosmire, G. J.; Ollerich, D. A.; Sandstead, H. H. Alterations in the postnatal development of the cerebellar cortex due to zinc deficiency. I. Impaired acquisition of granule cells. Brain Res., 1983, 271, 217-226.
26. Dvergsten, C. L.; Fosmire, G. J.; Ollerich, D. A.; Sandstead, H. H. Alterations in the postnatal development of the cerebellar cortex due to zinc deficiency. II. Impaired maturation of Purkinje cells. Brain Res., 1984, 318, 11-20.
27. Dvergsten, C. L.; Johnson, L.K.; Sandstead, H. H. Alterations in the postnatal development of the cerebellar cortex due to zinc deficiency. III. Impaired dendritic differentiation of basket and stellate cells. Brain Res., 1984, 318, 21-26.
28. Frederickson, C. J.; Koh, J. Y.; Bush, A. I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci., 2005, 6, 449-462
29. Taylor, C. G. Zinc, the pancreas, and diabetes: Insights from rodent studies and future directions. BioMetals, 2005, 18, 305-312.
30. James, M. M.; Charles, S. C. The mechanism of the insulin-like effects of ionic zinc. J. Biol. Chem., 1982, 257, 4362-4368.
31. Cunningham, J. J.; Fu, A. Z.; Mearkle, P. L.; Brown, R. G. Hyperzincuria in individuals with insulin-dependent diabetes mellitus: concurrent zinc status and the effect of high-dose zinc supplementation. Metab. Clin. Exp., 1994, 43, 1558-1562.
32. Coulson, L.; Dandona, P. Insulin-like effect of zinc on adipocytes. Diabetes, 1980, 29, 665-667.
33. Shisheva, A.; Gefel, D.; Shechter, Y. Insulinlike effects of zinc ion in vitro and in vivo. Preferential effects on desensitized adipocytes and induction of normoglycemia in streptozocin-induced rats. Diabetes, 1992, 41, 982-988.
34. Chen, M. D.; Liou, S. J.; Lin, P. Y.; Yang, V. C.; Alexander, P. S.; Lin, W. H. Effects of zinc supplementation on the plasma glucose level and insulin activity in genetically obese (ob/ob) mice. Biol. Trace Elem. Res., 1998, 61, 303-311.
35. Fugono, J.; Fujimoto, K.; Yasui, H.; Kawabe, K.; Yoshikawa, Y.; Kojima, Y.; Sakurai, H. Metallokinetic study of zinc in the blood of normal rats given insulinomimetic zinc(II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration. Drug Metab. Pharmacokinet., 2002, 17, 340-347.
36. World Health Organization. E. C., Environmental Health Criteria 221: Zinc, Geneva: World Health Organization, 2001, p. 360.
37. Brown, M. A.; Thom, J. V.; Orth, G. L.; Cova, P.; Juarez, J. Food poisoning involving zinc contamination. Arch Environ. Health, 1964, 34, 657-660.
38. Maret, W.; Sandstead, H. H. Zinc requirements and the risks and benefits of zinc supplementation. J. Trace Elem.Med. Biol. 2006, 20, 3-18.
39. Sandstead, H. H. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am. J. Clin. Nutr., 1995, 61, 621S-624S.
40. Reiser, S.; Smith Jr., J. C.; Mertz, W.; Holbrook, J. T.; Scholfield, D. J.; Powell, A. S.; et al. Indices of copper status in humans consuming a typical American diet containing either fructose or starch. Am., J. Clin., Nutr., 1985, 42, 242-251.
41. Porea, T. J.; Belmont, J. W.; Mahoney, D. H. Zinc-induced anemia and neutropenia in an adolescent. J. Pediatr., 2000, 136, 688-690.
42. Salzman, M. B.; Smith, E. M.; Koo, C. Excessive oral zinc supplementation. J. Pediatr. Hematol, Oncol., 2002, 24, 582-584.
43. Faber, C.; Gabriel, P.; Ibs, K. H.; Rink, L. Zinc in pharmacological doses suppresses allogeneic reaction without affecting the antigenic response. Bone Marrow Transplant, 2004, 33, 1241-1246.
44. Leitzmann, M. F.; Stampfer, M. J.; Wu, K.; Colditz, G. A.; Willett, W. C.; Giovannucci, E. L. Zinc supplement use and risk of prostate cancer. J. Natl. Cancer Inst., 2003, 95, 1004-1007.
45. Penland, J. G.; Milne, D. B.; Davis, C. W. Moderately high zinc intake impairs verbal memory of healthy postmenopausal women on a low copper diet. Trace Elements in Man and Animals, vol. 10, ed. By Roussel, A. M.; Anderson R. A.; Favier, A. E. Kluwer Academic/ Plenum, Evian, 2000, p. 1025-1030, 1172 pp.
46. Nordberg, G.; Sandström, B.; Becking, G.; Goyer, R. A. Essentiality and toxicity of trace elements: Principles and methods for assessment of risk from human exposure to essential trace elements. J. Trace Elem. Exp. Med., 2000, 13, 141-153.
47. Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 2001, 414, 821-827.
48. Gallwitz, B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol., 2006, 31, 133-147.
49. Bodmer, M.; Meier, C.; Krähenbühl, S.; Jick, S. S.; Meier, C. R. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care, 2008, 31, 2086-2091.
50. Thompson, K. H.; Lichter, J.; LeBel, C.; Scaife, M. C.; McNeill, J. H.; Orvig, C. Vanadium treatment of type 2 diabetes: A view to the future. J. Inorg. Biochem., 2009, 103, 554-558.
51. Balk, E. M.; Tatsioni, A.; Lichtenstein, A. H.; Lau, J.; Pittas, A. G. Effect of chromium supplementation on glucose metabolism and lipids: A systematic review of randomized controlled trials. Diabetes Care, 2007, 30, 2154-2163.
52. Stapleton, S. R. Selenium: An insulin-mimetic. Cell Mol. Life Sci., 2000, 57, 1874-1879.
53. Kinlaw, W. B.; Levine, A. S.; Morley, J. E.; Silvis, S. E.; McClain, C. J. Abnormal zinc metabolism in type II diabetes mellitus. Am. J. Med., 1983, 75, 273-277.
54. Honnorat, J.; Accominotti, M.; Broussolle, C.; Fleuret, A. C.; Vallon, J. J.; Orgiazzi, J. Effects of diabetes type and treatment on zinc status in diabetes mellitus. Biol. Trace. Elem. Res., 1992, 32, 311-316.
55. Simon, S. F.; Taylor, C. G. Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp. Biol. Med., 2001, 226, 43-51.
56. Kojima Y.; Yoshikawa Y. Zinc(II) complexes with anti-diabetic effect. Vitamins, 2005, 79, 155-165.
57. Sakurai, H.; Katoh, A.; Yoshikawa, Y. Chemistry and biochemistry of insulin-mimetic vanadium and zinc complex. Trial for treatment of diabetes mellitus. Bull. Chem. Soc. Rev., 2006, 79, 1645-1664.
58. Yoshikawa, Y.; Kawabe, K.; Tadokoro, M.; Suzuki, Y.; Yanagihara, N.; Nakayama, A.; Sakurai, H.; Kojima, Y. New zinc(II) complexes with tetradentate amino acid derivatives: Structure characterization, solution chemistry, and in vitro insulinomimetic activity. Bull. Chem. Soc. Jpn., 2002, 75, 2423-2432.
59. Yoshikawa, Y.; Ueda, E.; Miyake, H.; Sakurai, H.; Kojima, Y. Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-Ay mice with type 2 diabetes mellitus. Biochem. Biophys. Res. Commun., 2001, 281, 1190-1193.
60. Adachi, Y.; Yoshida, J.; Kodera, Y.; Sakurai, H. A Highly potent insulin-mimetic zinc(II) complex with a Zn(S2O2) coordination mode: Bis(1,6-dimethyl-3-hydroxy-5-methoxy-2-pentyl -1,4-dihydropyridine-4-thionato)zinc(II). Chem. Lett., 2005, 34, 656-657.
61. Yoshikawa, Y.; Kondo, M.; Sakurai, H.; Kojima, Y. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n=3 and 4) coordination modes. J. Inorg. Biochem., 2005, 99, 1497-1503.
62. Saha, T. K.; Yoshikawa, Y.; Sakurai, H. A [meso-tetrakis(4-sulfonatophenyl)porphyrinato] zinc(II) complex as an oral therapeutic for the treatment of type 2 diabetic KKAy mice. ChemMed-Chem, 2007, 2, 218-225.
63. Yoshikawa, Y.; Adachi, Y.; Sakurai, H. A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex. Life Sci., 2007, 80, 759-766.
64. Adachi, Y.; Yoshida, J.; Kodera, Y.; Kiss, T.; Jakusch, T.; Enyedy, E. A.; Yoshikawa, Y.; Sakurai, H. Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes. Biochem. Biophys. Res. Commun., 2006, 351, 165-170.
65. Yoshikawa, Y.; Ueda, E.; Sakurai, H.; Kojima, Y. Anti-diabetes effect of Zn(II)/carnitine complex by oral administration. Chem. Pharm. Bull., 2003, 51, 230-231.
66. Song, M. K.; Rosenthal, M. J.; Hong, S.; Harris, D. M.; Hwang, I.; Yip, I.; Golub, M. S.; Ament, M. E.; Go, V. L. Synergistic antidiabetic activities of zinc, cyclo (his-pro), and arachidonic acid. Metabolism, 2001, 50, 53-59.
67. Song, M. K.; Hwang, I. K.; Rosenthal, M. J.; Harris, D. M.; Yamaguchi, D. T.; Yip, I.; Go, V. L. Anti-hyperglycemic activity of zinc plus cyclo (his-pro) in genetically diabetic Goto-Kakizaki and aged rats. Exp. Biol. Med., 2003, 228, 1338-1345.
68. Fujimura, H.; Nozaki, M.; Tanaka, S.; Akaoka, T.; Natsuki, R. Tranexamic acid/Zn complexes with anti-diabetic effect. JP Patent, 2001-247458.
69. Katoh, A.; Matsumura, Y.; Yoshikawa, Y.; Yasui, H.; Sakurai, H. Evaluation of insulin-mimetic activities of vanadyl and zinc(II) complexes from the viewpoint of heterocyclic bidentate ligands. J. Inorg. Biochem., 2009, 103, 567-574.
70. Kojima, Y.; Sakurai, H. Zn organic compounds with hypoglycemic effect. JP Patent, 2001-220348.
71. Karmaker, S.; Saha, T. K.; Yoshikawa, Y.; Sakurai, H. A zinc(II)/poly(gamma-glutamic acid) complex as an oral therapeutic for the treatment of type-2 diabetic KKAy mice. Macromol. Biosci., 2009, 9, 279-286.
72. Narad, S. R.; Mishra, N. N; Pandey, P.; Kumar, A. Antidiabetic activity of some oral hypoglycemic agents with metal ions on animal model. Ind. J. Exp. Biol., 1996, 34, 81-82.
73. Vanco, J.; Marek, J.; Trávnícek, Z.; Racanská, E.; Muselík, J.; Svajlenová, O. Synthesis, structural characterization, antiradical and antidiabetic activities of copper(II) and zinc(II) schiff base complexes derived from salicylaldehyde and beta-alanine. J. Inorg. Biochem., 2008, 102, 595-605.
74. Baum, M. K.; Shor-Posner, G.; Campa, A.; Zinc status in human immunodeficiency virus infection. J. Nutr., 2000, 130, 1421S-1423S.
75. Ho, E.; Quan, H.; Tsai, Y. H.; Lai, W.; Bray, T. M. Dietary zinc supplementation inhibits NFkappaB activation and protects against chemically induced diabetes in CD1 mice. Exp. Biol. Med., 2001, 226, 103-111.
76. Tang, X. H.; Shay, N. F. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3T3-L1 fibroblasts and adipocytes. J. Nutr., 2001, 131, 1414-1420.
77. 2+) stimulate glucose transport activity by post-insulin receptor kinase mechanism in rat adipocytes. J. Biol. Chem., 1989, 264, 16118-16122.
78. Wu, W.; Wang, X.; Zhang, W.; Reed, W.; Samet, J. M.; Whang, Y. E.; Ghio, A. J. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J. Biol. Chem., 2003, 278, 28258-28263.
79. Hasse, H.; Maret, W. Protein tyrosine phosphatases as target of the combined insulinomimetic effect of zinc and oxidants. Biometals, 2005, 18, 333-338.
80. Ueda, E.; Yoshikawa, Y.; Sakurai, H.; Kojima, Y.; Kajiwara, N. M. In vitro alpha-glucosidase inhibitory effect of Zn(II) complex with 6-methyl-2-picolinmethylamide. Chem. Pharm. Bull., 2005, 53, 451-452.
81. Yoshikawa, Y.; Ueda, E.; Kojima, Y.; Sakurai, H. The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life Sci., 2004, 75, 741-751.
82. 2) enhances insulin signaling pathway in 3T3-L1 adipocytes. J Inorg. Biochem., 2007, 101, 692-699.
83. Yasui, H.; Nishimura, H.; Haba, H.; Hirunuma, R.; Enomoto, S.; Sakurai, H. Analysis of skin distribution of 65Zn in hairless mice treated with 65Zn-labeled zinc compounds by oral supplementation. RIKEN Accel. Prog. Rep., 2005, 38, 119.
84. Yasui, H.; Nishimura, H.; Haba, H.; Enomoto, S.; Sakurai, H. Difference in property of skin penetration between 65Zn(II) ion and its complex topically applied on skin of live hairless mice. RIKEN Accel. Prog. Rep., 2006, 39, 118.
85. Jansen, J.; Karges, W.; Rink, L. Zinc and diabetes - clinical links and molecular mechanisms. J. Nutr. Biochem., 2009, 20, 399-417.
86. Ring, D. B.; Johnson, K. W.; Henriksen, E. J.; Nuss, J. M.; Goff, D; Kinnick, T. R.; Ma, S. T.; Reeder, J. W.; Samuels, I.; Slabiak, T.; Wagman, A. S.; Hammond, M.-E. W.; Harrison, S. D. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes, 2003, 52, 588-595.
87. Dokken, B. B.; Sloniger, J. A.; Henriksen, E. J. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle. Am. J. Physiol., 2005, 288, E1188-E1194.
88. Holst, B.; Egerod, K. L.; Jin, C.; Petersen, P. S.; Ostergaard, M. V.; Hald, J.; Sprinkel, A. M. E.; Storling, J.; Mandrup-Poulsen, T.; Holst, J. J.; Thams, P.; Orskov, C.; Wierup, N.; Sundler, F.; Madsen, O. D.; Schwartz, T. W. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction. Endocrinology, 2009, 150, 2577-2585.